Max Healthcare Institute shares witnessed a decline in afternoon trade on Tuesday, trading at ₹1,076.80, down 2.14% from its previous close as of 1:08 pm. According to reports from Moneycontrol, the stock remains a constituent of the NIFTY 50 index, maintaining its position as a notable entity in the healthcare sector backed by solid financial performance and corporate governance.
The company has demonstrated consistent growth in its annual financial performance over the past five years. As reported by Moneycontrol, consolidated revenue increased from ₹3,931.46 crore in 2022 to ₹8,373.45 crore in 2026, representing a significant growth trajectory. Net profit surged from ₹605.05 crore in 2022 to ₹1,442.41 crore in 2026, indicating an increase of 34.07% in net profit from 2025 to 2026. Earnings Per Share (EPS) climbed from ₹6.25 in 2022 to ₹14.83 in 2026, further reinforcing the company's financial strength.
The company's consolidated quarterly revenue for the quarter-ending March 2026 stood at ₹2,142.89 crore, an increase from ₹1,909.74 crore in the quarter-ending March 2025. According to Moneycontrol reports, net profit for the quarter-ending March 2026 was ₹342.22 crore, up from ₹319.00 crore in the same quarter of the previous year. This quarterly performance highlights sustained growth and operational efficiency across the company's operations.
Max Healthcare Institute's financial ratios indicate a strong operational and leverage position. As reported by Moneycontrol, the Return on Networth / Equity (ROE) for March 2026 was 13.42%, a slight increase from 11.46% in March 2025. The Debt to Equity ratio remained stable at 0.27x for both March 2025 and March 2026, suggesting a controlled leverage position. The company announced a Final Dividend of ₹2.00 per share (20%) on May 21, 2026, effective July 3, 2026, following a Final Dividend of ₹1.50 per share (15%) announced on May 20, 2025.
